Compare FirstEnergy Corp. (FE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Sana Biotechnology Inc — how do they compare? FirstEnergy Corp. trades at $48.93 (market cap $28.13B), while Sana Biotechnology Inc trades at $3.38 (market cap $987.94M). The key difference: FirstEnergy Corp. is far larger — about 28.5× Sana Biotechnology Inc's market cap, and FirstEnergy Corp. pays a 3.82% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FE | SANA | |
|---|---|---|
Market Cap | $28.13B | $987.94M |
Sector | Utilities | Health |
52-Week High | $51.91 | $5.92 |
52-Week Low | $40.30 | $2.68 |
Enterprise Value | $56.14B | $962.13M |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $49.22, up 1.63% with a bullish technical signal. The stock shows consistent revenue growth, reaching $15.09B in 2025, and maintains a net income margin of 6.86%. Analyst consensus is a Buy with a $52.00 price target, supported by strong cash flow from operations of $3.70B. Recent news highlights growth from data center demand and a $36B investment plan.
Outlook remains positive due to strategic investments and rising energy demand, but risks include high debt levels and regulatory pressures. The stock offers steady growth potential with a dividend yield, though investors should monitor execution of capital expenditures and interest rate impacts on financing costs.
SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
